Primary tabs
The list of publications is indicative and may not include all publications.
Opposite Prognostic Impact of Single PTEN-loss and Mutations in Early High-risk Breast Cancer..
Cancer Genomics Proteomics. 16(3), 195-206.
(2019).
Interaction Between Beta-Catenin and EGFR Expression by Immunohistochemistry Identifies Prognostic Subgroups in Early High-risk Triple-negative Breast Cancer..
Anticancer Res. 36(5), 2365-78.
(2016).
The impact of paclitaxel and carboplatin chemotherapy on the autonomous nervous system of patients with ovarian cancer..
BMC Neurol. 16(1), 190.
(2016).
p85 protein expression is associated with poor survival in HER2-positive patients with advanced breast cancer treated with trastuzumab..
Pathol Oncol Res. 21(2), 273-82.
(2015).
Differential expression of the insulin-like growth factor receptor among early breast cancer subtypes..
PLoS One. 9(3), e91407.
(2014).
The androgen receptor as a surrogate marker for molecular apocrine breast cancer subtyping..
Breast. 23(3), 234-43.
(2014).
Prevalence of BRCA1 mutations in familial and sporadic greek ovarian cancer cases..
PLoS One. 8(3), e58182.
(2013).
Improved outcome of high-risk early HER2 positive breast cancer with high CXCL13-CXCR5 messenger RNA expression..
Clin Breast Cancer. 12(3), 183-93.
(2012).
Triple-negative phenotype is of adverse prognostic value in patients treated with dose-dense sequential adjuvant chemotherapy: a translational research analysis in the context of a Hellenic Cooperative Oncology Group (HeCOG) randomized phase III trial..
Cancer Chemother Pharmacol. 69(2), 533-46.
(2012).
Prognostic significance of UBE2C mRNA expression in high-risk early breast cancer. A Hellenic Cooperative Oncology Group (HeCOG) Study..
Ann Oncol. 23(6), 1422-7.
(2012).